1. Pink Sheet

Medicare Price Negotiation Law Fixes Face ‘Big Problem,’ Former Trump Official Says

 
• By Cathy Kelly

Health policy experts and biopharma supply chain stakeholders discuss prospects for legislation reforming the Inflation Reduction Act, pharmacy benefit manager practices, and the 340B program during a recent conference.

Will Republican Focus On US Government Spending Cuts Hamper IRA Fixes? • Source: Shutterstock

Efforts to amend the Inflation Reduction Act to narrow the types of drugs subject to the law’s Medicare price negotiation program may have trouble succeeding in a political environment that will be increasingly focused on cutting spending, according to former Trump Administration official Joe Grogan.

Key Takeaways

  • Legislative relief from Medicare negotiation for small molecule and orphan drugs may be increasingly challenging.

Grogan, who served as director of the White House Domestic Policy Council and associate director for health programs at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Last Minute Course Shifts, Focus On Unknowns: What Sponsors Should Learn From Prasad’s Interventions

 
• By Sarah Karlin-Smith

The once and current CBER director’s justification for his COVID-19 decision stands as a warning of the uncertainty sponsors, particularly those in the vaccine space, may now face at FDA.

Novaxovid And mNexspike Reviewers

 
• By Bridget Silverman

Pink Sheet Drug Review Profile feature listing FDA staff who conducted the reviews of Novavax and Moderna's post-pandemic COVID-19 vaccines

GLP-1s In Crosshairs As Employers Worry About Health Costs – And Their Own Reliance On Rebates

 
• By Cathy Kelly

Business Group on Health annual employer survey highlights fast-growing Rx costs, led by the GLP-1 drugs, and payer strategies for controlling them. Policy prescriptions are unclear, though, since employers are loath to leave PBMs and nervous about pending changes to Medicare and Medicaid.